September 20, 2024

High-Dose Vitamin D3 Does Not Provide Benefit for Metastatic Colorectal Cancer

Researchers evaluated the addition of high-dose vitamin D3 to standard treatment for metastatic colorectal cancer. They presented their findings at the ESMO Congress 2024.

The ASCO Post

September 20, 2024

LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC

The ASCO Post

September 20, 2024

NIAGARA Trial: Perioperative Durvalumab Reduced Risk of Recurrence or Death vs Neoadjuvant Chemotherapy Alone in Muscle-Invasive Bladder Cancer

The ASCO Post

September 20, 2024

5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in Hepatocellular Carcinoma

The ASCO Post

September 20, 2024

Long-Term Outcomes With Adjuvant Trastuzumab for 9 Weeks or 1 Year in HER2-Positive Breast Cancer: Analysis From SOLD Trial

The ASCO Post

September 11, 2024

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

The ASCO Post

Latest Headlines

October 01, 2024

Ocular Side Effects of Systemic Chemotherapy Agents

New Retinal Physician

October 01, 2024

Industry Insider: Apellis Pharmaceuticals' Dr. Phil Ferrone

Ophthalmology Management

October 01, 2024

Ocular Side Effects of Systemic Chemotherapy Agents

Retinal Physician

September 27, 2024

Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost

The ASCO Post

September 27, 2024

CABINET Trial Supports Multitargeted Tyrosine Kinase Inhibitor for Advanced Neuroendocrine Tumors

The ASCO Post

September 27, 2024

Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population

The ASCO Post

Daily News

Stay up to date with the latest clinical headlines.

Conference Coverage

All Conference News View Conference Calendar

2024 ASCO Quality Care Symposium

September 27, 2024

Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost

The ASCO Post

September 27, 2024

Community-Academic Partnership May Successfully Reduce Radon-Related Lung Cancer Risk in Native Population

The ASCO Post

September 27, 2024

Olanzapine May Reduce Chemotherapy-Induced Nausea and Improve Quality of Life Among Patients With Cancer

The ASCO Post

2024 IASLC WCLC

September 26, 2024

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

The ASCO Post

September 24, 2024

Ifinatamab Deruxtecan Shows Activity in Extensive-Stage Small Cell Lung Cancer

The ASCO Post

September 18, 2024

AEGEAN Update Confirms Benefit of Perioperative Durvalumab in Resectable NSCLC

The ASCO Post

2024 European Breast Cancer Conference

September 24, 2024

Phase III ALEXANDRA/IMpassion030: No Survival Benefit for Adjuvant Atezolizumab in Triple-Negative Breast Cancer

The ASCO Post

August 01, 2024

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The ASCO Post

July 18, 2024

New Genetic Test May Predict Response to Immunotherapy in Triple-Negative Breast Cancer

The ASCO Post

Clinical Guidelines

September 24, 2024

ASCO Issues First Guideline Specific to Locally Advanced Rectal Cancer

The ASCO Post

September 24, 2024

A Clinical Trial Has Halted Progression of Merkel Cell Carcinoma and Allowed Me to Pursue My Love of Music

The ASCO Post

September 20, 2024

Retifanlimab Plus Chemotherapy May Extend Progression-Free Survival in Patients With Squamous Cell Anal Carcinoma

The ASCO Post

September 17, 2024

FDA Approves Ribociclib With an Aromatase Inhibitor and Ribociclib/Letrozole Co-Pack for Early High-Risk Breast Cancer

The ASCO Post

Commentary & Perspectives

July 10, 2023

Expert Point of View: Pamela L. Kunz, MD and Corrie Marijnen, MD, PhD

The ASCO Post

January 25, 2023

Communicating Prognosis: A Core Competency of Patient-Centered Oncology Care

The ASCO Post

June 09, 2023

Rethinking Prior Authorization

The ASCO Post

October 25, 2023

Gender Equity in Academic Hematology: Where There’s a ‘WiL,’ There’s a Way

The ASCO Post

FDA & Government News

September 26, 2024

FDA Approves Osimertinib in Stage III NSCLC After Chemoradiotherapy

The ASCO Post

September 18, 2024

FDA Draft Guidance on Conducting Multiregional Oncology Clinical Trials

The ASCO Post

September 18, 2024

FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

The ASCO Post

July 18, 2023

First Oral Medication to Treat Moderate-to-Severe Crohn’s Disease Earns FDA Approval

Mount Sinai New York

Business Management

September 19, 2024

Carbon and Keystone Industries Celebrate Milestone of 1,000,000 Dental Parts Printed with Keystone Materials on Carbon Printers

Inside Dentistry

April 01, 2023

Change is Constant

Inside Dental Hygiene

February 08, 2023

Machine Learning and the Power to Outsmart Cancer

Cedars-Sinai Pulse

June 10, 2024

How the Museum of Medicine and Biomedical Discovery Aims to Bring Scientific Achievements of the Past, Present, and Future to Life

The ASCO Post

Trending Now

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dental Technology

Inside Dentistry

Special Issues

The ASCO Post

JADPRO

JNCCN

JNCCN 360

Corneal Physician

Glaucoma Physician

New Retinal Physician

Ophthalmology Management

Ophthalmic Professional

Presbyopia Physician

Retinal Physician

Contact Lens Spectrum

Eyecare Business

Optometric Management

Presbyopia Physician

5-Year Analysis of Phase III HIMALAYA Confirms Survival Benefit of STRIDE in Hepatocellular Carcinoma

Long-Term Outcomes With Adjuvant Trastuzumab for 9 Weeks or 1 Year in HER2-Positive Breast Cancer: Analysis From SOLD Trial

HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC

Latest Headlines

Daily News

Recommendations

Featured Videos

Conference Coverage

2024 ASCO Quality Care Symposium

2024 IASLC WCLC

2024 European Breast Cancer Conference

Clinical Guidelines

Commentary & Perspectives

FDA & Government News

Business Management